Baker Bros. Capital (GP), LLC

Filings by Baker Bros. Capital (GP), LLC span 15 companies, the busiest being Incyte Corp, Genomic Health Inc and Idera Pharmaceuticals, Inc. We count 311 filings; the first trade dates from 24 February 2006 and the latest from 27 January 2012.

The open-market side counts 180 purchases for €316k alongside 91 sales for €4.6M. On balance, insiders were net sellers of €4.3M. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Outside the open market, there are 6 share grants. So far in 2012, the count stands at no purchases and 3 sales.

A typical purchase (the median) is worth €430. For 60 purchases whose 90-day window has closed, the share price was higher on day 90 than the day after publication in 55% of cases, with a median move of +11.8%. These figures describe past trades and do not predict future prices.

The latest filing, published on 31 January 2012, reports an open-market sale of €10k in Vaxgen Inc. The last insider purchase was made public on 9 June 2011, 5,616 days ago. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. US insiders must file a Form 4 within two business days of a trade. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.